The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global preimplantation genetic testing market exhibited XX growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different XX. These insights are included in the report as a major market contributor.
Preimplantation genetic testing (PGT) identifies abnormal embryos and allows the transfer of genetically normal embryos. It reduces the trauma of multiple failed in vitro fertilization (IVF) cycles and early miscarriages. It also protects children from inherited monogenic disorders. As a result, it is used to treat individuals at high risk of having babies with specific genetic aberrations. It is also utilized in hematological disorders to cure the affected child and in cases of advanced maternal age to avoid the birth of a syndromic child. Nowadays, PGT technology is integrated with Assisted Reproductive Technology (ART) procedures to offer the best outcomes to patients around the world.
Chromosomal aneuploidies are one of the leading causes of infertility and maternal age-related reduced fertility. A significant rise in the birth rates and incidences of spontaneous miscarriages represents one of the key factors positively influencing the demand for PGT to reduce the need for multiple IVF cycles. In addition, as the risk of miscarriage grows gradually with the woman’s age, the emerging delayed parenthood trend is catalyzing the demand for PGT across the globe. Apart from this, the rising medical tourism and improving diagnostic modalities are other factors stimulating the market growth. Moreover, the introduction of novel techniques that include microarray and genome sequencing is propelling the market growth. Furthermore, with the discovery of deoxyribonucleic acid (DNA) within the blastocoele fluid (BF) of blastocysts and in spent embryo culture media (SCM), researchers are focusing on developing non-invasive methods of PGT. In confluence with this, the escalating demand for minimally invasive (MI) procedures is contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global preimplantation genetic testing market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, procedure, technology and application.
Breakup by Product:
Breakup by Procedure:
Breakup by Technology:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., Oxford Gene Technology IP Limited (Sysmex Corporation), PerkinElmer Inc., Quest Diagnostics Incorporated, The Cooper Companies Inc and Thermo Fisher Scientific.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Procedure, Technology, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., Oxford Gene Technology IP Limited (Sysmex Corporation), PerkinElmer Inc., Quest Diagnostics Incorporated, The Cooper Companies Inc and Thermo Fisher Scientific.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at